Evidence map›Paper›PMID 29706350›Full record

ArticleAmerican journal of human genetics2018

A Saturation Mutagenesis Approach to Understanding PTEN Lipid Phosphatase Activity and Genotype-Phenotype Relationships.

Taylor L Mighell, Sara Evans-Dutson, Brian J O'Roak

Open access · bronzeAbstract read
In one paragraph

Article in American journal of human genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed, 1 pooled it
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

144 citing papers in PubMed, 1 synthesis or guideline pooled it, 230 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Phenotype-Specific Recalibration of MAVE Data Enables Repurposing ofmedRxiv : the preprint server for health sciences · 2026
    Article
  12. Functional dissection ofProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  13. Review
  14. Clinicogenomic Landscape and Function ofJCO precision oncology · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. A scalable approach to resolving variants of uncertain significance.bioRxiv : the preprint server for biology · 2026
    Article
  19. Review
  20. Review

84 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Taylor L MighellNeuroscience Graduate Program, Oregon Health & Science University, Portland, OR 97239, USA; Department of Molecular & Medical Genetics, Oregon Health & Science University, Portland, OR 97239, USA.
Sara Evans-DutsonDepartment of Molecular & Medical Genetics, Oregon Health & Science University, Portland, OR 97239, USA.
Brian J O'RoakDepartment of Molecular & Medical Genetics, Oregon Health & Science University, Portland, OR 97239, USA. Electronic address: oroak@ohsu.edu.
Oregon Health & Science University · US

Funding

MULTIDISCIPLINARY TRAINING IN NEUROENDOCRINOLOGYT32DK007680 · NIDDK · OREGON HEALTH & SCIENCE UNIVERSITY · PI GOODMAN, RICHARD H. · 1991 to 2015
$6.8M
Massively parallel functional analyses of human PTEN variantsF31HD095571 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI MIGHELL, TAYLOR · 2018 to 2019
$88k
NICHD NIH HHS F31 HD095571NIDDK NIH HHS T32 DK007680
6 · The paper itself

Abstract

Phosphatase and tensin homolog (PTEN) is a tumor suppressor frequently mutated in diverse cancers. Germline PTEN mutations are also associated with a range of clinical outcomes, including PTEN hamartoma tumor syndrome (PHTS) and autism spectrum disorder (ASD). To empower new insights into PTEN function and clinically relevant genotype-phenotype relationships, we systematically evaluated the effect of PTEN mutations on lipid phosphatase activity in vivo. Using a massively parallel approach that leverages an artificial humanized yeast model, we derived high-confidence estimates of functional impact for 7,244 single amino acid PTEN variants (86% of possible). We identified 2,273 mutations with reduced cellular lipid phosphatase activity, which includes 1,789 missense mutations. These data recapitulated known functional findings but also uncovered new insights into PTEN protein structure, biochemistry, and mutation tolerance. Several residues in the catalytic pocket showed surprising mutational tolerance. We identified that the solvent exposure of wild-type residues is a critical determinant of mutational tolerance. Further, we created a comprehensive functional map by leveraging correlations between amino acid substitutions to impute functional scores for all variants, including those not present in the assay. Variant functional scores can reliably discriminate likely pathogenic from benign alleles. Further, 32% of ClinVar unclassified missense variants are phosphatase deficient in our assay, supporting their reclassification. ASD-associated mutations generally had less severe fitness scores relative to PHTS-associated mutations (p = 7.16 × 10

Indexed as

Genetic Association StudiesAllelesCluster AnalysisHigh-Throughput Nucleotide SequencingHumansMutagenesisMutationPTEN PhosphohydrolasePTEN Phosphohydrolaseautism spectrum disordercancerCowden syndromedeep mutation scanninggenotype-phenotypeprotein functionPTENPTEN hamartoma tumor syndrometumor suppressorvariants of uncertain significance

Identifiers

PMID29706350
PMCPMC5986715
OpenAlexW2794121543

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.